Literature DB >> 1874935

Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings.

A Dunaif1, G Green, R G Phelps, M Lebwohl, W Futterweit, L Lewy.   

Abstract

Acanthosis nigricans (AN) is a frequent clinical finding in hyperandrogenic women. Its presence has been used to subgroup such women. We performed this study in order to determine the actual histological prevalence of AN and its relationship to sex hormone levels and insulin action. Insulin-mediated glucose disposal was determined by the euglycemic clamp technique, and neck or axillary skin biopsies were graded blind for the presence and severity of AN in lean and obese women with the polycystic ovary syndrome (PCO) and in age- and weight-matched normal ovulatory controls. AN was present on clinical examination in 11 of 13 obese PCO, 3 of 6 lean PCO, 4 of 14 obese normal, and 0 of 4 lean normal women. AN was present on histological examination in 13 of 13 obese PCO, 5 of 6 lean PCO, 13 of 14 obese normal, and 1 of 4 lean normal women. The severity of histological AN was most highly correlated with insulin-mediated glucose disposal (r = -0.61; P less than 0.001) rather than fasting (r = 0.46; P less than 0.05) or glucose-stimulated insulin levels (r = 0.48; P less than 0.01). The only sex steroid correlated with histological AN was dehydroepiandrosterone sulfate (r = 0.46; P less than 0.01). We conclude that 1) clinical skin examination was very insensitive for detecting AN; 2) the best biochemical correlate of histological AN was decreased insulin action, rather than insulin or androgen levels per se; and 3) AN is a very common epiphenomenon of insulin resistance, and its clinical presence should not be used as a criterion for stratifying hyperandrogenic women.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1874935     DOI: 10.1210/jcem-73-3-590

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

2.  The expression of resistin in adipose tissues of patients with polycystic ovary syndrome and insulin resistance.

Authors:  Yongli Chu; Qing Cui; Guijiao Feng; Zhiyun Song; Xueqiang Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

3.  p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice.

Authors:  Yingli Wang; Xueyan Zhou; Kurun Oberoi; Robert Phelps; Ross Couwenhoven; Miao Sun; Amélie Rezza; Greg Holmes; Christopher J Percival; Jenna Friedenthal; Pavel Krejci; Joan T Richtsmeier; David L Huso; Michael Rendl; Ethylin Wang Jabs
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

4.  Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.

Authors:  A Dunaif; J Xia; C B Book; E Schenker; Z Tang
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 5.  The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms.

Authors:  R Dumitrescu; C Mehedintu; I Briceag; V L Purcarea; D Hudita
Journal:  J Med Life       Date:  2015 Apr-Jun

6.  Acanthosis Nigricans as a Clinical Predictor of Insulin Resistance in Obese Children.

Authors:  Young Kwon Koh; Jae Hee Lee; Eun Young Kim; Kyung Rye Moon
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2016-12-28

Review 7.  Transcriptional Regulation of Glucose Metabolism: The Emerging Role of the HMGA1 Chromatin Factor.

Authors:  Eusebio Chiefari; Daniela P Foti; Riccardo Sgarra; Silvia Pegoraro; Biagio Arcidiacono; Francesco S Brunetti; Manfredi Greco; Guidalberto Manfioletti; Antonio Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-03       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.